Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OER Glibenclamide for Neuropathic Pain in MS
NCT07221799Phase 1Not yet recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of glibenclamide in neuropathic pain (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Maximum Plasma Concentration at 10 hours, Safety and Tolerability and 5 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
glibenclamide
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT07221799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221799.